AIM To compare therapeutic responses of a vasculardisrupting-agent,combretastatin-A4-phosphate(CA4P),among hepatocellular carcinomas(HCCs)and implanted rhabdomy
AIM To evaluate the prognostic power of different molecular data in liver cancer.METHODS Cox regression screen and least absolute shrinkage and selection operat
Hepatocellular carcinoma(HCC)is the fifth most common cancer and is the second leading cause of cancer death.Since the diagnosis of HCC is difficult,in many cas